What dose of aspirin (mg) should be used for secondary prevention?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 23, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Aspirin Dosing for Secondary Prevention

For long-term secondary prevention after ischemic stroke, TIA, or cardiovascular disease, use aspirin 75–100 mg daily (typically 81 mg in the United States). 1

Recommended Maintenance Dose

  • Aspirin 75–100 mg once daily is the evidence-based dose for secondary prevention in patients with non-cardioembolic ischemic stroke, TIA, myocardial infarction, or established coronary artery disease 1

  • The 81 mg tablet is the most common low-dose formulation in the United States and provides equivalent efficacy to higher doses while minimizing bleeding complications 1

  • Doses above 100 mg (such as 325 mg) increase gastrointestinal bleeding risk without providing additional cardiovascular protection 1

Loading Dose in Acute Settings

  • For acute ischemic stroke or TIA, administer a single loading dose of 160–325 mg aspirin after intracranial hemorrhage has been excluded on neuroimaging 1, 2

  • If the patient received intravenous alteplase, delay aspirin until at least 24 hours post-thrombolysis to reduce hemorrhagic risk 1, 2

  • After the loading dose, transition to maintenance therapy of 75–100 mg daily starting on day 2 1, 2

Special Circumstances: Dual Antiplatelet Therapy

  • For minor stroke (NIHSS ≤3) or high-risk TIA (ABCD2 ≥4) presenting within 24 hours, use dual antiplatelet therapy: loading doses of aspirin 160–325 mg plus clopidogrel 300–600 mg, followed by aspirin 75–100 mg daily plus clopidogrel 75 mg daily for exactly 21 days 1, 2

  • After 21 days of dual therapy, switch to single antiplatelet therapy (aspirin 75–100 mg daily OR clopidogrel 75 mg daily) indefinitely 1, 2

  • Do not extend dual antiplatelet therapy beyond 21–30 days because bleeding risk outweighs benefit (hazard ratio for major hemorrhage 2.22–2.32) 1, 2

Alternative Antiplatelet Agents

  • Clopidogrel 75 mg daily is an equally effective alternative for patients with aspirin allergy, intolerance, or diabetes 1, 3

  • Aspirin 25 mg plus extended-release dipyridamole 200 mg twice daily is another acceptable alternative regimen 1, 2

Diabetes-Specific Recommendations

  • For diabetic patients with established cardiovascular disease, use aspirin 75–162 mg daily for secondary prevention 1

  • The dose range of 75–162 mg is acceptable, but 75–100 mg is preferred to minimize bleeding while maintaining efficacy 1

Common Pitfalls to Avoid

  • Never use aspirin doses below 75 mg daily because efficacy data are limited 1, 3

  • Never routinely prescribe 325 mg daily for chronic maintenance because this increases bleeding without improving outcomes 1

  • Never continue dual antiplatelet therapy indefinitely in stable patients without a specific cardiac indication (e.g., recent stent placement) 1, 2

  • Never substitute aspirin for thrombolysis or mechanical thrombectomy in eligible acute stroke patients 1, 2

Evidence Quality

  • The 75–100 mg daily maintenance dose recommendation is supported by Class I, Level A evidence from multiple large randomized trials and international guidelines 1, 3

  • The ADAPTABLE trial (38% diabetic patients) showed no difference in cardiovascular events or bleeding between 81 mg and 325 mg daily, supporting use of the lower dose 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Loading Dose of Antiplatelet Drugs in Ischemic CVA

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Antiplatelet Therapy for Long‑Term Secondary Prevention of Atherosclerotic Cardiovascular Disease

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.